Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Herpesvirus Vaccine
Virus expressing HSV-2 glycoproteins protects against HSV-2 challenge
September 8th, 2004
Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. According to published research from the United States, "A recombinant Oka (ROka) varicella-zoster virus (VZV) vaccine was constructed that expresses herpes simplex virus type 2 (HSV-2) glycoproteins B (gB) and D (gD). Guinea pigs received one of four inocula: uninfected cells; recombinant Oka VZV infected cells; recombinant Oka VZV expressing HSV-2 gB/gD (ROka-gB2/gD2) infected cells; or heat-inactivated ROka-gB2/gD2 infected cells. Only animals inoculated with ROka-gB2/gD2 developed high titers of neutralizing antibodies to HSV-2." "Animals...
Source: Vaccine Weekly (2004-09-08)
|
